



## Supplemental Figures

### A. Unlabeled polatuzumab vedotin (DAR ~3.4)




### B. [<sup>3</sup>H]-MMAE-polatuzumab vedotin (DAR ~3.4)




**Supplemental Figure 1.** The average drug to antibody ratios (DAR) were calculated from the integrated areas of the DAR species resolved by hydrophobic interaction chromatography detected at UV 280 nm. (A) Unlabeled reference polatuzumab vedotin with a DAR ~3.4. (B) [<sup>3</sup>H]-MMAE-polatuzumab vedotin with a DAR ~3.4.

A.



B.



**Supplemental Figure 2.** The tissue distribution of polatuzumab vedotin and polatuzumab antibody after a single dose via IV administration. (A) The tissue and blood radioactivity from intact ( $^{125}\text{I}$  radioactivity—solid bar) and catabolized ( $^{111}\text{In}$  subtracted with  $^{125}\text{I}$  radioactivity—open bar) polatuzumab vedotin dosed at tracer ( $\sim 3\text{--}4$   $\mu\text{g}/\text{kg}$ ) plus 10  $\text{mg}/\text{kg}$  of unlabeled polatuzumab vedotin up to 14 days post administration. (B) The tissue and blood radioactivity from intact ( $^{125}\text{I}$  radioactivity—solid bar) and catabolized ( $^{111}\text{In}$  subtracted with  $^{125}\text{I}$  radioactivity—open bar) polatuzumab antibody dosed at tracer ( $\sim 3\text{--}4$   $\mu\text{g}/\text{kg}$ ) plus 10  $\text{mg}/\text{kg}$  of

unlabeled polatuzumab antibody up to 14 days post administration. The data are represented as the mean  $\pm$  SD. n = 3 per time point. S. Intestine: small intestine; L. Intestine: large intestine; B. Marrows: bone marrows; A. gland: adrenal glands; DRG: dorsal root ganglions.